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The CLN6 vLINCL is caused by molecular defects in CLN6 gene coding for an ER resident transmembrane protein whose function is
unknown. In the present study gene expression profiling of CLN6-deficient fibroblasts using cDNA microarray was undertaken in order to provide
novel insights into the molecular mechanisms underlying this neurodegenerative fatal disease. Data were validated by qRT-PCR. Statistically
significant alterations of expression were observed for 12 transcripts. The two most overexpressed genes, versican and tissue factor pathway
inhibitor 2, are related to extracellular matrix (ECM), predicting changes in ECM-related proteins in CLN6-deficient cells. Transcript profiling
also suggested alterations in signal transduction pathways, apoptosis and the immune/inflammatory response. Up-regulated genes related to
steroidogenesis or signalling, and the relationship between cholesterol dynamics and glycosphingolipid sorting, led to investigation of free
cholesterol and gangliosides in CLN6-deficient fibroblasts. Cholesterol accumulation in lysosomes suggests a homeostasis block as a result of
CLN6p deficiency. The cholesterol imbalance may affect structure/function of caveolae and lipid rafts, disrupting signalling transduction pathways
and sorting cell mechanisms. Alterations in protein/lipid intracellular trafficking would affect the composition and function of endocytic
compartments, including lysosomes. Dysfunctional endosomal/lysosomal vesicles may act as one of the triggers for apoptosis and cell death, and
for a secondary protective inflammatory response. In conclusion, the data reported provide novel clues into molecular pathophysiological
mechanisms of CLN6-deficiency, and may also help in developing disease biomarkers and therapies for this and other neurodegenerative diseases.
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The neuronal ceroid-lipofuscinoses (NCL) are a group of
autosomal recessive neurodegenerative diseases with an inci-
dence ranging from 0.1 to 7 per 100.000 live births. Clinical
features include visual failure, seizures, progressive mental and
motor deterioration, and premature death. There is accumulation
of autofluorescent lipofuscin-like material in the lysosomes of
neurons and other cell types. Three classical subtypes (infantile,
late-infantile and juvenile) are described based on age of onset,
clinical course and the ultrastructural appearance of membrane-
bound inclusions. Presently, six genetically distinct types are
recognized [1].
Classical infantile, late-infantile and juvenile are caused by
mutations in CLN1, CLN2 and CLN3 genes, respectively.
CLN1p/PPT1 and CLN2p/TPP1 are soluble lysosomal enzymes,
whereas CLN3 is an intrinsic membrane protein. Variant late-
infantile phenotype (vLINCL) exhibits subtle, but distinct clinical
and histological differences from classical LINCL. The age of
onset may be as late as 6 years of age, with death occurring
between the age of 13 and 30 years. In the vast majority of cases
inclusion bodies consist of a mix of curvilinear and fingerprint-
like bodies. vLINCL phenotype arises from mutations in CLN5,
CLN6 or CLN8 coding for proteins with predicted membrane
topology [2]. Primary lysosomal dysfunction in NCL is only
evident for CLN1 and CLN2.
The CLN6 gene was cloned in 2002 [3,4] and unlike other
NCLs no prevalent mutation has been identified. A total of 22
mutations distributed across the entire coding region have been
described [5,6], and they were found in ethnic groups from
different countries (Argentina, Costa Rica, Portugal, Greece,
Italy, India, Morocco, Pakistan, Turkey, Venezuela, North
America and Sudan). The gene encodes a 311 amino-acid
protein with seven putative transmembrane domains whose to-
pology is not yet known. Recent data suggests that CLN6p, 27–
30 kDa, is an ER-resident protein [7,8]. CLN8p is also an ER
protein and may recycle between ER and ERGIC [9]. As a
member of the eukaryotic family of TLC (TRAM-Lag1p-
CLN8)-domain homologues [10] CLN8p may act as a sterol-
sensing-domain protein or intracellular chaperone and/or have a
role in biosynthesis or transport of lipid molecules.
In the present study global gene expression was analyzed in
CLN6-deficient human fibroblasts in order to gain insight into
the pathophysiological mechanisms operating in the disease.
The altered expression pattern generated by cDNA microarray
and confirmed by qRT-PCR suggests that changes in ECM
architecture and signalling are likely to be involved in
development and progression of disease. Expression of genes
involved in stress/apoptosis and in immune/inflammatory res-
ponses was also altered, supporting the notion that these may be
important for neurodegeneration. Transcript profiling data and
the observed intralysosomal accumulation of cholesterol and
gangliosides in CLN6-deficient fibroblasts suggest that dis-
turbed cholesterol homeostasis is an important pathogenic cause.
The cholesterol homeostasis block associated with a disruption
of lipid/protein sorting mechanisms may lead to impairment of
the function of the endosomal system.2. Materials and methods
2.1. Cell lines
Cultured skin fibroblasts were obtained from 5 CLN6 patients belonging to 5
unrelated families (one American and four Portuguese). The American patient
was homozygous for the mutation c.214G>T [3]. Three Portuguese patients
were homozygous for c.460_462delATC leading to deletion of isoleucine 154.
The other patient was a compound heterozygous carrying I154del mutation in
one allele and [c.829_832delGTCG; c.837delG] in the other resulting in a
frameshift after tryptophan 276 [5]. These cases were previously reported as
vLINCL patients [11]. In the Portuguese I154del homozygous patients the
disease onset occurred around 4 years of age and skin biopsy was performed
about 1 year and half later. Although the disease progression was similar until
they became bedridden, the life expectancy was distinct. A similar disease
progression was observed for the Portuguese I154del compound heterozygote.
The ultrastructural study was performed later but a similar profile, a mix of
curvilinear and fingerprint inclusions, was observed.
Fibroblasts were grown at 37 °C with 5% of CO2 in Dulbecco's Medium,
supplemented with antibiotics and 10% of fetal bovine serum. All culture
reagents were purchased from GibcoBRL. All fibroblasts cell lines used were
subjected to only two to three passages.
2.2. Affymetrix microarray data analysis
Global gene expression profiles were compared in human fibroblast cell lines
from three normal adult individuals and five CLN6 patients. Total cellular RNA
was isolated from 5×106 to 1×107 cells using Rneasy Mini Kit (Qiagen),
according to manufacturer's instructions. Samples were analyzed using
Affymetrix HuFL6800 GeneChip, which consists of probes for a total of 7129
human genes. After scanning probe arrays, data were stored, converted to .txt
files, imported intoMicrosoft Excel, and used for data analysis and interpretation.
Genechip data were analyzed with the Affymetrix software, dChip,
Microsoft Excel, Cluster, and S-plus (Seattle, WA) software. Raw data from
Affymetrix CEL files were normalized and quantified using dChip [12]. Only
genes with consistent hybridization indicators (AbsCall from Affymetrix
software 5.0) from all replicates, and with greater than 2-fold changes (CLN6
deficient versus normal), were included. A further statistical test using modified
t-test was performed using SAM software [13]. Expression levels were
visualised by Cluster software with an established colour code, red for up-
regulation, green for down-regulation. Classification of function of individual
genes was based in part on information from LocusLink (http://www.ncbi.nlm.
nih.gov/LocusLink).
2.3. Quantitation of mRNA by real time PCR
Total RNAwas isolated from 5×106 to 1×107 cells using the Roche Applied
Science Kit according to the manufacturer's manual. The RNA was reverse
transcribed using the “First-strand cDNA synthesis kit” (Amersham Bios-
ciences) following the manufacturer's protocol. Real-time PCR analysis was
performed on an Applied Biosystems ABI PRISM 7000 Sequence Detection
System. Primer and probe sequences (Table 1) were designed to specifically
amplify cDNA using Primer Express software 2.0 or purchased as assays-
on-demand (Applied Biosystems). PCR reactions were prepared in a final
volume of 50 μl using 1× TaqMan Universal PCR Master Mix (Applied
Biosystems), 300 nM of each primer, 250 nM of probe and 1 ng of RNA
converted to cDNA. The conditions used for assays-on-demand were according
to manufacturer's recommendations. Thermal cycling conditions comprised an
initial AmpErase UNG incubation at 50 °C for 2 min, AmpliTaq Gold DNA
Polymerase activation at 95 °C for 10 min, and 40 cycles of denaturation (95 °C
for 15 s), annealing and extension (60 °C for 1 min). All PCR efficiencies were
above 95%. Relative quantification of gene expression was performed using the
standard curve method comprising four serial dilution points (ranging from
0.1 ng to 50 ng). For each sample, the RNA extraction procedure was repeated
twice and each batch analyzed independently three times by calculating the
average Ct values from duplicate PCR reactions. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH, Applied Biosystems, #431098) gene expression was
Table 1
Primers and probes used in real time RT-PCR
Gene GeneBank accession no. Forward primer/Reverse primer/Probe Exon boundary
AKR1C3/3α-HSD D17793 TGGAAAAGTAATATTTGACATAGTGGATCT Exon 4/Exon 5
GCCAATCCTGCATCCTTACAC
TGTACCACCTGGGAGGCCATGGA
PP5/TFPI-2 D29992 CGATGCTTGCTGGAGGATAGA Exon 2/Exon 3
ACACTGGTCGTCCACACTCACT
AAAGTTCCCAAAGTTTGCCGGCTGC
GARP Z24680 GCCATGAGACCCCAGATCCT Exon 2/Exon 3
CTGGCACGAGACCTTCTTGTC
CACAACACCAAGACAAAGTGCCCTGTAAGATG
BCHE M16474 Hs00163746_m1 a Exon 2/Exon 3
C1R M14058 Hs00354278_m1 a –
CSPG2 U16306 GCAAGATACCGAGACATGTGACTATG –
GACGGCATTCCCGTTCAG
ACTTTGCCCATCGACGCACAT
CLU NM_001831 Hs00156548_m1 a Exon 3/Exon 4
HSP70-2/HSPA1B M59830 ACCAAGCAGACGCAGATCTTC –
GCCCTCGTACACCTGGATCA
CCTACTCCGACAACCAACCCGGG
QPCT X71125 Hs00202680_m1 a Exon 2/Exon 3
CAV2 NM_001233 GATCCCCACCGGCTCAA Exon 1/Exon 2
ACCGGCTCTGCGATCACA
TCGCATCTCAAGCTGGGCTTCGA
LOXL2 U89942 TGAAGAATGTCACCTGCGAGAA Exon 5/Exon 6
GATGTAGGCACCGCCTCTCA
ACGGACCCTCGAGATTCCGGAAAG
RRAS2 M31468 Hs00273367_m1 a Exon 1/Exon 2
RAP1 X63465 Hs00221760_m1 a Exon 12/Exon 13
RTVP-1 X91911 AACCAACAGCCAGTGATATGCTATAC Exon 1/Exon 2
GGCCCATGCTTTTGCAATT
TGACTTGGGACCCAGCACTAGCCC
AIM1 U83115 GGAGACGATCATTTGCCGTTT Exon 7/Exon 8
CTTCTAGCAAATACTGATGACCGGTAA
TCTATGAAAGTTCTAAGAGGCATTTGGGTTGCAT
a Primers and probes ordered to Applied Biosystems as assays-on-demand.
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Ct variance ≤ 0.10 as assessed by variance using Excel computer software. The
relative quantification of the mRNA was determined through the ratio of the
normalized expressions of the CLN6 and control samples. t-test was used to
assess differences in gene expression between patient and control cell lines.
Two-sided P values of less than 0.05 were considered statistically significant.
Data were expressed as a mean±SD.
2.4. Free cholesterol assay by filipin staining and fluorescence
microscopy
Fibroblasts were stained with filipin and viewed by fluorescence microscopy
according to Kruth et al. [14]. Briefly, cells were plated into chamber slides
(Labteck slip, Nunc) in Dulbeccos MEMmedia (GibcoBRL) supplemented with
10% of fetal bovine serum, at 37 °C with 5% of CO2 for 16 h. The media was
replaced by MEM with 10% LPDS (Lipoprotein-deficient Serum, Sigma) and
cells cultured for 3 days before human LDL was added (50 μg/ml). The LDL
fraction was prepared using blood from normal donors following the procedure
described by Havel et al. [15]. After a 24-h incubation with LDL in 10% LPDS
media, cells were washed with PBS (three times for 5 min), fixed with
formaldehyde 3.7% (v/v) for 10 min at room temperature. After washing twice
with PBS, 0.1 mg/ml of fresh Filipin (Sigma) was added to each slide and kept in
the dark for 1 h. For colocalization study, after cell fixation they were
permeabilized with 0.5% Triton X-100/PBS for 10 min at RT and blocked with
PBS containing 1% bovine serum albumin (BSA) for 30 min. Cells were then
incubated with mouse monoclonal (IgG1) Lamp 1 (H4A3) (Sigma) primary
antibody previously diluted 1:100 in PBS for 12–16 h at 4 °C. The secondary
antibody, chicken anti-mouse IgG-FITC (Sigma), diluted 1:100 in PBS was usedalong with Filipin reagent. After washing in PBS, slides were mounted using
VectaShield (Vector Laboratories) and visualised with a Nikon Eclipse E400
fluorescence microscope (λexc.=364 nm; λemi.=475 nm). Cells were imaged using a
Nikon Coolpix 950 camera and processed with Adobe Photoshop CSV8.0 program.
2.5. Immunohistochemistry for human gangliosides
Cells were fixed with 3.7% formaldehyde in PBS pH 7.4 for 10 min at RT,
rinsed twice with PBS, and permeabilized with 0.5% Triton X-100/PBS for
10 min at RT. After two washes, cells were blocked with PBS containing 1%
bovine serum albumin (BSA) for 30 min. Cells were then incubated with
monoclonal primary antibody anti-GM2 (IgM) [16], a kind gift from Dr. T. Tai
fromMetropolitan Institute of Medical Science in Japan, previously diluted 1:50
in PBS, for 12–16 h at 4 °C. After washing three times with PBS cells were
incubated for 1 h with secondary antibody (anti-mouse (Fab')2 IgM μ-chain
specific, conjugated with fluoresceine) previously diluted 1:75 (Sigma). After
washing with PBS, coverslips were mounted with VectorShield (Vector
Laboratories), imaged with a Nikon Eclipse E400 fluorescence microscope
(λexc.=494 nm; λemi.=518 nm) and charge-coupled device Nikon Coolpix 950
camera.
2.6. Assay for glycosaminoglycans in urine
Urine was collected over a period of 48 h keeping the sample refrigerated
during collection. After collection aliquots were stored at −20 °C. Urinary
creatinine was estimated using BioMérieux kit (BioMérieux, France) according
to manufacturer's instructions. Quantification of total urinary glycosaminogly-
cans (GAGs) was performed by Alcian Blue complex formation method [17].
Fig. 1. Group of genes with altered expression (>2-fold) in CLN6-deficient human fibroblasts in comparison to normal. Colours represent relative levels of gene
expression, with the brightest red indicating a higher level of gene expression, black indicating level of expression similar to normal and green depicting lower level of
expression. Each horizontal line represents a gene; each column represents a cell line. Lanes 1 to 4 correspond to control cell lines; lanes 5 to 10 are CLN6 cell lines
(5 and 6-homozygous for c.214G>T; 7, 9 and 10-homozygous for I154del; 8-compound heterozygous for I154del). (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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mg GAG/mmol creatinine. Qualitative analysis of GAGs was determined by
electrophoresis on cellulose acetate strips according to the procedure previously
described [18], and expressed as percentage after densitometric scanning of
Alcian Blue stained strips.3. Results
3.1. Global gene expression changes in CLN6-deficient
fibroblasts
Global gene expression patterns were generated from
Affymetrix HuFL6800 Genechip microarrays using total RNA
isolated from cultured skin fibroblasts from five CLN6 patientsTable 2
Gene expression profiling: expression changes greater than 2-fold in CLN6-human
Symbol Description
3α-HSD/AKR1C3 Aldo-keto reductase family I, member C3 (3-α-hydro
TFPI-2 Tissue factor pathway inhibitor 2
PP5 Placental protein 5
GARP Glycoprotein A repetitions predominant
BCHE Butyrylcholinesterase
C1R Complement component 1, r subcomponent
CSPG2 Chondroitin sulphate proteoglycan 2 (versican)
TRPM2/CLU Testosterone-repressed message 2 (clusterin, complem
SP-40, sulfated glycoprotein 2, apolipoprotein J)
HSPA1B7 HSP70-2 Human HMC class III heat shock HSP70-2 gene (HL
QPCT Glutaminyl-peptide cyclotransferase (glutaminyl cycl
CAV2 Caveolin 2
LOXL2 Lysyl oxidase-like 2
RRAS2 Ras-like protein TC21
RAP1 GTP-GDP dissociation stimulator 1
RTVP1 Glioma pathogenesis-related protein/RTVP-1 protein
AIM1 Absent in melanoma 1/Human non-lens beta gamma-
TFPI2 and PP5 refer to the same gene. Fold change is calculated as ratio between the
Average Difference values (arbitrary units).
a Mean expression values from CLN6 patients, n=5.
b Mean expression values from normal controls, n=3.and three normal controls. Using a 2-fold change in expression
as the experimental cut-off that would imply significance,
changes in gene expression were observed for 15 transcripts
(Fig. 1), nine genes were up-regulated and six down-regulated
compared to normal controls (Table 2). Those alterations were
further confirmed by a second methodological approach, qRT-
PCR (see below). Some other NCL-types were analyzed aside
with CLN6 and control cell lines (data not shown). Distinct
groups of genes with an altered expression profile were
identified in other NCL-deficient fibroblasts, thus indicating
that the expression profile here reported for CLN6 is specific of
this variant. Of notice is the fact that higher variability in gene
expression was observed for CLN6 cell lines than for other
NCL-diseased fibroblasts tested using the same technicalfibroblasts as compared to normal cell lines
Fold
change
Expression level
(mean±SD)
CLN6 a Normal
controls b
xysteroid dehydrogenase, type II) 7.5 9109±4602 1216±559
6.2 6252±6001 1013±225
4.3 6532±4910 1507±973
3.7 7561±4557 2056±535
3.1 269±85 86±15
2.9 14781±7746 5088±1266
2.8 9195±3049 3282±1458
ent lysis inhibitor, 2.8 14398±5097 5229±1228
A), 70 kDa protein 1B 2.5 3033±2389 1217±155
ase) 2.1 2049±405 991±405
−2.0 3086±1381 6106±1388
−2.0 4704±2753 9512±1077
−2.0 2999±1003 6088±1947
−2.2 1055±347 2285±1032
−2.3 3088±1102 6951±1928
crystallin like complex −2.9 964±300 2759±905
CLN6 and normal control cell lines. Expression levels were taken as Affymetrix
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ciated with the CLN6 deficiency. If this variability has
physiological meaning at either protein or phenotypic level is
presently unknown.
3.2. Validation of gene expression profile by real-time RT-PCR
(qRT-PCR)
RNA was isolated from CLN6-deficient cell patients and
normal human fibroblasts and used to examine the expression of
the 16 genes by qRT-PCR (TaqMan chemistry) in order to
validate cDNAmicroarray data. For normalization purposes, the
housekeeping gene GAPDH was used. This gene has been
widely used as a constitutively expressed control gene in RT-
PCR studies [19]. Moreover, microarray data showed that its
expression remained unchanged in CLN6-deficient cells when
compared with control cells (1.04-fold). Under the qRT-PCR
experimental conditions, BCHE gene expression level was
undetectable. This result was not surprising since genechip
profiling revealed a significantly lower expression level for
BCHE as compared with all the other genes (Table 2). TFPI2 and
PP5 refer to the same gene and are, therefore, treated as one.
TFPI2 is the designation used throughout the text.
Data obtained for the remaining 14 transcripts is presented in
Table 3. From the set of fourteen genes, 12 (86%) had a
statistically significant fold change in qRT-PCR (P<0.05). For
the remaining two, HSP70-2 and RAP21, with a mean fold
change of 1.2 and 1.1 respectively; the expression was
considered unchanged between CLN6 and control cells. The
qRT-PCR confirmed expression changes observed in genechip
profiling for 7 up-regulated genes (about 60% of total). The
remaining 5 genes down-regulated in microarray were found up-
regulated by qRT-PCR. This apparent discrepancy can be
explained by the low differential expression (2.3-fold or less)Table 3
Relative quantitation of transcripts by real time RT-PCR
Gene qRT-PCR Genechip
Expression level (mean±SD) Mean
fold
change
P Mean
fold
change
CLN6 a Normal controls b
3α-HSD 5.15±3.37 1.00±0.06 5.2 <0.05 7.5
TFPI2/PP5 20.0±15.9 1.00±0.13 20 <0.05 4.3
GARP 4.98±2.31 1.00±0.11 5.0 <0.05 3.7
C1R 3.10±0.55 1.00±0.14 3.1 <0.005 2.9
CSPG2 48.1±23.3 1.00±0.09 48 <0.05 2.8
TRPM2 1.47±0.34 1.00±0.19 1.5 <0.05 2.8
HSP70-2 1.22±0.43 1.00±0.11 1.2 2.5
QPCT 2.59±0.28 1.00±0.25 2.5 <0.005 2.1
CAV2 1.59±0.24 1.00±0.11 1.6 <0.005 −2.0
LOXL2 9.98±4.11 1.00±0.08 10.0 <0.05 −2.0
TC21 3.92±1.19 1.00±0.11 3.9 <0.005 −2.0
RAP1 1.14±0.20 1.00±0.08 1.1 −2.2
RTVP1 5.03±3.00 1.00±0.04 5.0 <0.05 −2.3
AIM1 2.22±0.67 1.00±0.07 2.2 <0.05 −2.9
Fold change is calculated as ratio between the CLN6 and normal control cell
lines.
a Mean expression values from CLN6 patients, n=3.
b Mean expression values from normal controls, n=2.observed in microarray analysis for most of down-regulated
genes. Furthermore, microarray data can be implicated by cross-
hybridization from other genes [20], even though the observa-
tions are statistically consistent. On the other hand, real time
allowed the detection of 1.5-fold change, or even less, implying
that changes in expression of genes can be detected with higher
reproducibility and sensitivity by qRT-PCR than genechip
profiling. Thus, using microarray to rapidly screen the tran-
scriptome disease and then validating the results by gene-
specific qRT-PCR, may lead to reliable disease biomarkers.
3.3. Functional categorization of gene products
The 12 up-regulated genes can be grouped into 4 functional
categories: extracellular matrix (ECM) remodelling, cell signal-
ling, apoptosis and immuno/inflammatory response. Since many
of these genes have more than one function, they could be
assigned to more than one functional class. About 60% of the
overexpressed genes in CLN6-deficient cells are related to cell
surface, cell adhesion, cell proliferation and cytoskeleton. This
category reflects the overlap that may occur between the func-
tions of proteins located at the cell surface. It includes CSPG2,
LOXL2, TFPI2, GARP [21,22], RTVP1, TC21, AIM1 and
CLU. The most pronounced expression changes were observed
for versican (CPGS2) [23–25] and the tissue factor pathway
inhibitor 2 (TFPI-2), a serine protease inhibitor reported at high
levels in extracellular matrix [26,27], supporting a role for CLN6
in ECM remodelling.
The group of genes related to apoptosis include CSPG2,
LOXL2 [28], RTVP1, AIM1 and CLU. Up-regulation of genes
encoding molecular chaperones, namely clusterin and small heat
shock proteinsAIM1 is not surprising since the storagematerial in
CLN6-deficient cells is mainly of a proteinaceous nature. The
overexpression of these genes may protect CLN6 cells against
apoptotic cell death induced by heat shock, oxidative stress and
neurodegeneration, as reported for other neurodegenerative
conditions [29–32]. Component C1R [33] and clusterin [34,35]
(also implicated in inhibition of complement attack) have also
been associated with the immuno/inflammatory response. Over-
expression of TFPI-2 in CLN6-deficient cell lines is observed. An
anti-inflammatory function is attributed to its inhibitory role of
matrix metalloproteinases involved in ECM architecture remo-
delling [36]. The advancement of both proinflammatory and anti-
inflammatory mechanisms probably suggests the secondary
nature of inflammation in the neurodegenerative process.
Gene expression profiling also suggests the involvement of
diverse signalling molecules in the pathogenesis of CLN6. The
gene products included in this category dictate alterations in
neurotransmission (QPCT and 3α-HSD), steroidogenic hor-
mones (3α-HSD and CLU) and intracellular signalling cascades
(CAV2 and TC21) [37].
3.4. Cholesterol, gangliosides and GAGs imbalance in
CLN6-deficient fibroblasts
The altered expression profile of a set of genes comprising
3α-HSD, CSPG2, LOXL2, QPCT, CLU and CAV2 implies
Fig. 2. (a) Evaluation of free cholesterol accumulation by Filipin Staining. Cells from individuals with: 1-no pathology; 2-Niemann–Pick type C; 3-GM1-
Gangliosidosis; 4-GM2-Gangliosidosis (B1 variant); 5 and 6-CLN6 variant (homozygous for I154del, lane 10 of Fig. 1, and compound heterozygous for I154del, lane
8 of Fig. 1, respectively). (b) Co-localization of Filipin Staining with the lysosomal marker, Lamp 1. Cells from a CLN6 cell line (lane 10 of Fig. 1): 1-with Filipin
staining; 2-marked with Lamp 1; 3-co-localization of Filipin staining with Lamp 1.
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structure of lipid rafts and cofactor for signalling [38–44,30].
The observed expression changes would reflect physiological
compensatory mechanisms aiming to restore cholesterol
homeostasis in CLN6 disease. To address this hypothesis filipin
staining of CLN6-deficient human fibroblasts was performed to
detect free cholesterol. Cells from patients with Niemann–Pick
type C (NPC), gangliosidosis GM1 and GM2 (B1 variant) were
used as positive controls (Fig. 2a). Similarly to NPC and
gangliosidoses, CLN6-deficient cells cultured in the presence of
LDL showed filipin staining in perinuclear granules reflective
of lysosomal cholesterol accumulation. In normal control
fibroblasts relatively little cytoplasmatic fluorescence was
observed. The lysosomal distribution of the accumulated freeFig. 3. GM2 ganglioside accumulation in LSD skin fibroblasts. Cell lines from indiv
Pick type C; 4 and 5-CLN6 variant (homozygous for I154del, lane 10 of Fig. 1, andcholesterol in CLN6-deficient human fibroblasts was confirmed
by colocalization assay using Lamp 1 as lysosomal marker (Fig.
2b). Secondary glycosphingolipid accumulation has been
documented in human fibroblasts [45] and mouse models of
several LSDs [46]. This storage is accompanied by sequestra-
tion of free cholesterol in a manner similar to that observed in
primary gangliosidoses [47]. We investigated the accumulation
of ganglioside GM2 in CLN6-deficient fibroblasts by immu-
nofluorescence microscopy. Discrete punctate fluorescent
structures outlining the region of the nucleus were visualised
and appeared identical to those observed in NPC and GM2-
gangliosidoses (B1 variant) (Fig. 3). Secondary accumulation of
gangliosides related to a cholesterol disturbed homeostasis
might explain their intralysosomal trapping in CLN6 deficientiduals with: 1-no pathology; 2-GM2-Gangliosidosis (B1 variant); 3-Niemann–
compound heterozygous for I154del, lane 8 of Fig. 1, respectively).
Fig. 4. Glycosaminoglycan profile in urine from a CLN6 homozygous patient
for I154del. The level of GAGs was determined by Alcian Blue method. GAG
composition was assessed by monodimensional cellulose acetate gel electro-
phoresis. Urine samples: lane 1-control individual; lane 2-C, D and H refer to the
chondroitin sulphate, dermatan sulphate and heparin sulphate standards,
respectively; lane 3-CLN6 patient; lane 4-CLN6 patient after chondroitinase
ABC digestion; lane 5-CLN6 patient after chondroitinase B (dermatan sulphate)
digestion; lane 6-CLN6 patient after heparitinase III digestion.
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I154del homozygous patient but it is presently unclear if that
variability has any physiological meaning.
The two most over-expressed gene products (CSPG2 and
TFPI2) are related to abnormal turnover of proteoglycans.
Urinary GAGs were analyzed as a measure of lysosomal storage
in the kidney tubules, and, by association, as a measure of over-
all storage in other tissues. Two samples of urine were collected
from a CLN6-deficient patient homozygous for the mutation
I154del, at 15 and 17 years of age. The excreted GAGmean level
was higher when compared to normal age-matched controls
(8.0 mg/mmol creatinine; normal: 2.0–6.5 mg/mmol cretinine).
GAG profile was distinct in this patient as compared with con-
trol urines (Fig. 4). In control urines only one band (lane 1) co-
migrating with chondroitin sulphate was observed. In contrast, in
the CLN6-deficient patient urine three bands (lane 3) were clearly
observed. One large band co-migrating with chondroitin sulphate
and dermatan sulphate standards disappeared after digestion with
chondroitinase ABC (lane 4). Digestion with chondroitinase B
(lane 5) resulted in a band co-migratingwith chondroitin sulphate.
This profile suggests a higher heterogeneity of the chondroitin
sulphates in CLN6 urines in comparison with control samples.
The other band co-migrating with heparin sulphate standard was
sensitive to heparitinase digestion (lane 6). By densitometry,
heparin sulphate was estimated to correspond to about 25% of
total GAGs and was about 4-fold higher than controls.
4. Discussion
The variant late infantile form of NCL is a pan-ethnic disease
caused by mutations in the CLN6 gene. Typical inclusions are
seen in neuronal and other cell types. We hypothesized that the
gene expression profile of CLN6-deficient fibroblasts can
provide valuable clues into the molecular pathophysiologicalmechanisms operating in this disease. We analyzed global gene
expression by cDNA genechip profiling and used real time RT-
PCR to validate the microarray data. Fifteen genes were found
differentially expressed by genechip profile, and twelve
presented statistically significant changes by qRT-PCR. The
set of genes found up-regulated in CLN6-deficient fibroblasts
suggests a modulation of architecture of cell surface and signal
transduction pathways, apoptosis and immune/inflammatory
response in CLN6 variant.
The most remarkable over-expressed gene product was
versican (CSPG2), a cell surface proteoglycan whose glycos-
aminoglycan segment is a linear sulfated polysaccharide of
chondroitin-6-sulfate. CSPGs are major components of brain
extracellular matrix interacting with other matrix proteins, cell
surface receptors and transporters. Thus, the overexpression of
versican suggests alterations in cell–cell communication and
intracellular organization through either cytoskeleton rearrange-
ment or modulation of trafficking pathways. The altered expres-
sion of a set of genes, including TC21 and CAV2, supports the
importance of lipid raft signalling cascades in CLN6-deficiency
pathogenesis. For TC21, a member of the Ras superfamily of
small GTP-binding proteins, effector pathways include Ral,
phosphatidylinositol 3′ kinase and Ras/Raf/MAP kinase path-
ways [48]. Interestingly, the Ras/Raf/MAPK signalling cascade
regulates the expression of the ECM protease inhibitor TFPI2
[49,50] found to be overexpressed in CLN6-deficient cells.
Caveolin 2 is known to be present in specialized lipid domains,
caveolae, and acting as small signalling compartments. In
addition to concentrating signal transducers, caveolin binding
may functionally regulate the activation state of caveolae-
associated signalling molecules [51].
The altered expression of caveolin 2 and other gene products
related to cholesterol (3α-HSD, CSPGs, LOXL2, QPCT and
clusterin) point to a cholesterol homeostasis break as a con-
sequence of CLN6 deficiency.
No cholesterol accumulation was observed by HPTLC (un-
published results) corroborating data of previous studies in
CLN6-deficient animals using the same methodology [52].
Fluorescence microscopy of CLN6-deficient fibroblasts how-
ever showed intracellular accumulation of cholesterol in lyso-
somes (Fig. 2b). In addition to cholesterol, these cells were also
found to accumulate gangliosides. Given that GSLs and cho-
lesterol are constituents of caveolae and lipid rafts critical for
signal transduction events, in neurons and other cells, their co-
sequestration in lysosomes predicts defects in the composition,
trafficking, and/or recycling of raft components that may affect
endocytic function, [47,53], including lysosome biogenesis and
autophagy. These alterations would lead to the accumulation of a
broad spectrum of substrates as observed in NCL disease.
Interestingly, the involvement of lipid rafts and vesicular traf-
ficking in CLNp cell biology and pathophysiology is not without
precedent. Several lines of evidence suggest that CLN3p follows
the constitutive cell route, from ER to Golgi to plasma mem-
brane via early endosomes. Faulty trafficking leads to accumu-
lation of CLN3p and galactosylceramide in lysosomes [54]. In
these routes, whether exocytic, endocytic or both, CLN3p has
been localized to lipid rafts [55].
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GAGs was observed in the urine of an I154del homozygous
patient. As far as we know skeletal abnormalities have never been
reported for CLN6 patients. Nevertheless, GAGs, such as heparan
sulfate and dermatan sulfate (chondroitin sulfate B), were recently
reported to stimulate the activation of pro-TPP1 and to inhibit the
in vitro and in vivo activity of mature enzyme in a dose dependent
manner [56]. Interestingly, in CLN2-deficient cells we have also
observed an overexpression of versican by qRT-PCR (data not
shown). Like TPP1, a pH-dependent inhibition of enzyme activity
by GAGs has been documented for other lysosomal enzymes
[57,58], and alterations in intralysosomal pH have been reported
in fibroblasts from patients with different forms of NCL,
including CLN6 [59]. It may be that a pH-dependent inhibition
of GSL-degradative enzymes by GAGs contributes to secondary
storage of glycosphingolipids in CLN6-deficient cells.
Many of the transcripts up-regulated in CLN6 deficient
human fibroblasts are known to be expressed in the brain
[23,60–65,40]. Interestingly, 3α-HSD is known to regulate the
occupancy of the γ-aminobutyric acid (GABA) receptor by
converting 5α-dihydroprogesterone into 3α-hydroxy-5α-preg-
nan-20-one (allopregnanolone), a potent positive allosteric
effector of the GABA receptor chloride ion channel [38].
Recently, a substantial reduction in the synthesis of allopregna-
nolone has been reported in a mouse model for Niemann–Pick
type C, and administration of allopregnanolone delayed disease
progression [66,67]. Allopregnanolone is an anticonvulsant
neurosteroid [68], thus, the up-regulation of 3α-HSD, as
observed in CLN6 deficient fibroblasts, may suggest a compen-
satory mechanism for modulation of seizure susceptibility in
patients. Given the role of cholesterol in synaptic formation and
function, plasticity and neurodegeneration [69,70], disruption of
cholesterol homeostasis may contribute to pathogenesis of
neurodegenerative CLN6-deficiency.
In conclusion, the data reported here suggest that a disruption
of cholesterol homeostasis in CLN6 disease, in addition to
changes in extracellular matrix architecture remodelling,
signalling cascades and intracellular vesicular trafficking may
be important pathogenic factors. A balance between apoptotic
and anti-apoptotic mechanisms, as well as proinflammatory and
anti-inflammatory processes, may also contribute to disease
progression and severity. For the time being it is impossible to
know the precise sequence of the cellular events that eventually
will lead to development of the disease, i.e., which have a causal
role and which are more secondary as a reflection of a primary
event. It is reasonable to assume that once the cascade of events
is initiated each cellular response will have a retrograde effect
on the other cellular responses perhaps exacerbating their effect
on disease progression.
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